#Food and Drug Administration

Acting Commissioner Ned Sharpless will return to lead the National Cancer Institute.

The FDA and the DEA issued joint warning letters to several websites telling them to stop or face severe legal consequences.

Alert comes after 63 reports of such outcomes, largely in people who should not have received Mavyret, Zepatier or Vosevi.

A roundup of POZ’s reporting on studies presented at the Mexico City conference about HIV treatment, vaccines, PrEP and other concerns.

Researchers reached this conclusion after reviewing data on more than 30,000 people.

Stella Armstrong’s journey to a healthier life wasn’t easy.

Between August 2018 and January 2019, the FDA doubled the number of liver cancer treatments.

A placebo-controlled study of obeticholic acid showed it improved liver fibrosis with no worsening of non-alcoholic steatohepatitis.

The freezer section staples have been implicated in four major outbreaks over the past 20 years.

With the approval of Cyramza, there are now five targeted therapies for hepatocellular carcinoma.

Unused medication needs to be disposed of safely.

In a recent statement, the Food and Drug Administration underscored the need for better technologies to protect the nation’s blood supply.

Ned Sharpless has been appointed interim head of the regulatory agency after the unexpected resignation of the commissioner.

The head of the Food and Drug Administration cited a long commute and time away from family as reasons to step down.

McKesson is under scrutiny after claims it failed to identify, quarantine and investigate drug shipments that had been tampered with.

The FDA’s revision was based on two randomized trials of Viread (tenofovir disoproxil fumarate) use in 2- through 11-year-olds.